miR-134 miR-17～92基因簇与卵巢癌耐药的关系

摘要/Abstract

摘要：

目的检测并验证miR-134及miR-17～92基因簇在紫杉醇耐药与敏感卵巢癌细胞中的差异表达并探讨两者参与卵巢癌耐药的可能机制。方法 2010年10月至2012年12月于中国医科大学附属盛京医院，用Affymetrix GeneChip miRNA 芯片对紫杉醇耐药与敏感卵巢癌细胞miRNA基因表达谱进行分析。选取差异表达明显的miR-134 和miR-17～92基因簇，采用Real -time PCR方法进一步验证芯片结果。应用生物信息学分析软件预测miR-134 和miR-17～92基因簇各自潜在的靶基因并通过Western Blot对部分靶基因进行验证。结果与敏感卵巢癌SKOV3细胞相比，耐药卵巢癌SKOV3-TR30细胞中miR-134低表达，miR-17～92基因簇高表达。软件预测得到miR-134 基因簇潜在靶基因c-Myc，MRP1/ABCC1等共128个, 软件预测得到miR-17~92 基因簇潜在靶基因BIM，PTEN，ABCA1等共30个。与敏感卵巢癌SKOV3细胞相比，耐药卵巢癌SKOV3-TR30细胞中miR-134潜在靶基因c-Myc蛋白高表达；miR-17~92 基因簇潜在靶基因BIM蛋白低表达（[WTBX]P[WTBZ]均﹤0.05），PTEN蛋白虽表达增高但差异无统计学意义。结论 MicroRNA表达谱基因芯片可筛查出紫杉醇耐药与敏感卵巢癌细胞的差异表达基因。低表达miR-134和高表达的miR-17～92基因簇可能分别通过调节其潜在靶基因c-Myc及BIM蛋白表达参与卵巢癌化疗耐药。

关键词: miRNA表达谱基因芯片, 卵巢癌, 耐药, miR-17～92, miR-134 

Abstract:

Abstract:Objective To detect the differentially miRNA expression in paclitaxel sensitive and chemoresistant ovarian cancer cell lines, and to explore the molecular mechanism of drug resistance of ovarian cancer. Methods The expression profile of miRNA were detected with miRNA microarray chip hybridization and the compared array results were further validated by Real-time PCR and Western Blot. Potential miRNA targets were predicted by bioinformatic software. Results Compared with SKOV3 cell line, miR17－92 gene cluster with high expression while miRNA134 cluster with low expression was found in SKOV3-TR30 cells. It can be predicted by bioinformatic software that miR17－92 gene cluster has 30 target genes such as BIM，PTEN，ABCA1，C10orf46，CD4, while miRNA134 cluster has 128 target genes such as MRP1/ABCC1. Western Blot showed that compared with SKOV3 cells, BIM expression was decreased in SKOV3-TR30 cells,while c-Myc was in high expression in SKOV3-TR30 cells.Conclusion The differentially miRNA expression profiles in SKOV3 and SKOV3-TR30 can be obtained by miRNA microarray chip technology. MiR-17－92 cluster and miR-134 cluster may be involved in drug resistance of ovarian cancer by regulating their target genes,which provide a theoretical basis for the study of ovarian cancer chemoresistance.

Key words: miRNA microarray chip, ovarian cancer ;chemoresistance;miR-17－92 ;miR-134 

中图分类号:

R711.75

王丹丹，王敏，双婷，史聪,张萍，陶陶，史春雪，吴建磊. miR-134 miR-17～92基因簇与卵巢癌耐药的关系[J]. 中国实用妇科与产科杂志.

WANG Dan-dan, WANG Min, SHUANG Ting,SHI Cong, ZHANG Ping, TAO Tao,SHI Chun-xue, WU Jian-lei. . Differentially expressions of miR-134 and miR-17-92 clusters and ovarian cancer paclitaxel resistance. [J]. Acta Metallurgica Sinica.

参考文献

[1］ Zhang L,Huang J,Yang N,et al. MicroRNAs exhibit high frequency genomic alterations in human cancer [J]. Proc Natl Acad Sci USA, 2006, 103: 9136-9141.

[2］ Hatfield S,Ruohola-Baker H. microRNA and stem cell function[J]. Cell Tissue Res，2008，331: 57-66.

[3］ Calin GA, Sevignani C, Dumitru CD, et al. Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers[J].Proc Natl Acad Sci USA, 2004, 101: 2999-3004.

[4］ Wang YQ, Guo RD, Guo RM,et al.MicroRNA-182 promotes cell growth, invasion and chemoresistance by targeting programmed cell death 4 (PDCD4) in human ovarian carcinomas[J].Cell Biochem，2013，114(7):1464-1473.

[5］ Cittelly DM, Dimitrova I, Howe EN, et al.Restoration of miR-200c to ovarian cancer reduces tumor burden and increases sensitivity to paclitaxel[J].Mol Cancer Ther，2012，11(12):2556-2565.

[6］ Kong F, Sun C, Wang Z,et al.miR-125b confers resistance of ovarian cancer cells to cisplatin by targeting pro-apoptotic Bcl-2 antagonist killer 1[J]. Huazhong Univ Sci Technolog Med Sci， 2011，31(4):543-549.

[7］ Lagos-Quintana M, Rauhut R, Yalcin A,et al.Identification of tissue-specific microRNAs from mouse[J].Curr Biol， 2002，12(9):735-739.

[8］ Haller F, von Heydebreck A, Zhang JD,et al.Localization-and mutation-dependent microRNA(miRNA) expression signatures in gastrointestinal stromal tumours (GISTs), with a cluster of co-expressed miRNAs located at 14q32.31[J]. Pathol， 2010，220(1):71-86.

[9］ Hirota T, Date Y, Nishibatake Y,et al.Dihydropyrimidine dehydrogenase (DPD) expression is negatively regulated by certain microRNAs in human lung tissues[J]. Lung Cancer，2012，77(1):16-23.

[10］陶陶，王敏.化疗耐药及敏感卵巢癌细胞差异表达microRNA的筛查与组鉴定[J].中国医科大学学报.2013,2 (42):118-122.

[11］双婷，吴建磊，王敏，等．耐药与敏感卵巢癌组织中miRNA表达差异谱检测及分析[J]．中国实用妇科与产科杂志，2013，29（1）：33-37．

[12］ Kim DY, Kim MJ, Kim HB, et al. Suppression of multidrug resistance by treatment with TRAIL in human ovarian and breast cancer cells with high level of c-Myc[J].Biochim Biophys Acta,2011,1812(7): 796-805. 

[1]	李一帆, 李宁, 吴令英. 铂耐药复发卵巢上皮性癌的治疗[J]. 中国实用妇科与产科杂志, 2022, 38(5): 503-507.
[2]	李晶, 吴妙芳, 林仲秋. 《FIGO 2021妇癌报告》——卵巢癌、输卵管癌、腹膜癌诊治指南解读[J]. 中国实用妇科与产科杂志, 2022, 38(3): 301-309.
[3]	卢淮武, 吴斌, 许妙纯, 霍楚莹, 林仲秋. 《2022 NCCN卵巢癌包括输卵管癌及原发性腹膜癌临床实践指南（第1版）》解读[J]. 中国实用妇科与产科杂志, 2022, 38(3): 310-318.
[4]	张国楠, 石宇, 王登凤. 助力实现R0，减少铂耐药的发生——晚期卵巢癌广泛性壁层腹膜切除术的临床意义[J]. 中国实用妇科与产科杂志, 2022, 38(1): 9-12.
[5]	马丁. 卵巢癌研究进展与规范化治疗[J]. 中国实用妇科与产科杂志, 2021, 37(6): 601-604.
[6]	高庆蕾. 卵巢癌与基因检测的规范化[J]. 中国实用妇科与产科杂志, 2021, 37(6): 605-609.
[7]	黄鹤，冯艳玲，刘继红. 卵巢癌的初始与间歇性肿瘤细胞减灭术相关问题[J]. 中国实用妇科与产科杂志, 2021, 37(6): 609-613.
[8]	窦莎，李艺，崔恒. 初诊上皮性卵巢癌的一线化疗[J]. 中国实用妇科与产科杂志, 2021, 37(6): 613-616.
[9]	陈雨莲，史庭燕，臧荣余. 铂敏感复发卵巢癌手术相关问题与规范化诊疗[J]. 中国实用妇科与产科杂志, 2021, 37(6): 616-620.
[10]	邓黎，梁志清. 微创手术在卵巢癌治疗中的应用与争议[J]. 中国实用妇科与产科杂志, 2021, 37(6): 620-623.
[11]	袁增，宋坤，孔北华. 遗传性卵巢癌预防性附件切除术的相关问题与争议[J]. 中国实用妇科与产科杂志, 2021, 37(6): 623-627.
[12]	孟元光，叶明侠. 卵巢癌肿瘤细胞减灭术的并发症及防治[J]. 中国实用妇科与产科杂志, 2021, 37(6): 627-630.
[13]	蒋芳，向阳. 卵巢癌免疫治疗的现状与进展[J]. 中国实用妇科与产科杂志, 2021, 37(6): 630-634.
[14]	王登凤，张国楠. 卵巢癌靶向治疗的规范化[J]. 中国实用妇科与产科杂志, 2021, 37(6): 634-639.
[15]	张师前，李小平. 晚期上皮性卵巢癌新辅助化疗指征的快速指南（2021年版）[J]. 中国实用妇科与产科杂志, 2021, 37(4): 444-448.